保留前叶经尿道前列腺剜除术后前列腺特异性抗原的变化

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the changes of serum prostate-specific antigen(PSA)in patients with benign prostatic hyperplasia(BPH)after anterior lobe preserved transurethral plasmakinetic enucleation of prostate.Methods The clinical data of 85 patients with BPH who received anterior lobe preserved transurethral plasmakinetic enucleation in Nanhai Hospital of Southern Medical University from July 2017 to October 2020 were retrospectively analyzed.According to the size of prostate,they were divided into three groups:small group(<40 mL)20 cases,medium group(40-80 mL)49 cases and large group(>80 mL)16 cases.The serum PSA levels of patients in the three groups were compared before surgery,1,7 days after surgery,1,2 and 3 months after surgery.Results The PSA level of 85 patients on the first day after operation was higher than that before operation,with statistical significance(P<0.05).The PSA levels of the 1,7 day and 1 month after operation were compared with those of the previous time point,and the differences were statistically significant(P<0.05).There were no significant differences in PSA levels between 1,2 and 3 months after operation(P>0.05).The PSA levels before and 1 day after surgery were compared between three groups,and the differences were statistically significant(P<0.05).There were no significant differences in PSA levels between 7 days after surgery and 1,2 and 3 months after surgery(P>0.05).One month after surgery,the 95% value of PSA was 1.46 ng/mL.Conclusion There was no difference in the PSA levels of different volumes of prostate at one month after anterior lobe preserved transurethral plasmakinetic enucleation of prostate,and the PSA levels reached a stable level.The "baseline value" of PSA at one month after surgery was 1.46 ng/mL,which is helpful for the evaluation of the complete degree of BPH resection and the early detection of postoperative new prostate cancer.However,the "baseline value" may vary among patients with different BPH,and further study is needed.

Key words： Benign prostatic hyperplasia Prostate-specific antigen Transurethral plasmakinetic enucleation of prostate Anterior lobe preserved

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIN Yang-yan
	QIU Chun-ming
	YANG Yong
	SUN Can-biao
	ZHANG Guo-fei

Cite this article:

LIN Yang-yan,QIU Chun-ming,YANG Yong, et al. Change of prostate-specific antigen after anterior lobe preserved transurethral plasmakinetic enucleation of prostate[J]. 中国当代医药, 2021, 28(22): 135-138.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I22/135

[1]	黄健，王建业，孔垂泽，等.2019 版中国泌尿外科和男科疾病诊断治疗指南[M].北京：科学出版社，2020：207，209.
[2]	Abedi AR，Ghiasy S，Fallah-Karkan M，et al.The Management of Patients Diagnosed with Incidental Prostate Cancer：Narrative Review[J].Res Rep Urol，2020，12：105-109.
[3]	Lambert E，Goossens M，Palagonia E，et al.Changes in serum PSA after endoscopic enucleation of the prostate are predictive for the future diagnosis of prostate cancer[J].World J Urol，2020，10，1007.
[4]	Ferro M，De Cobelli O，Lucarelli G，et al.Beyond PSA：The Role of Prostate Health Index （phi）[J].Int J Mol Sci，2020，21（4）：1184.
[5]	Duffy MJ.Biomarkers for prostate cancer：prostate-specific antigen and beyond[J].Clin Chem Lab Med，2020，58（3）：326-339.
[6]	Wu CT，Huang YC，Chen WC，et al.The Predictive Role of Prostate-Specific Antigen Changes Following Transurethral Resection of the Prostate for Patients with Localized Prostate Cancer[J].Cancers（Basel），2020，13（1）：74.
[7]	林阳彦，邱春明，杨勇，等.保留前叶经尿道前列腺剜除术治疗前列腺增生的5年疗效分析[J].实用医学杂志，2020，36（24）：3394-3398.
[8]	韩苏军，张思维，陈万青，等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志，2013，18（4）：330-334.
[9]	Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2018，68（6）：394-424.
[10]	Wong MC，Goggins WB，Wang HH，et al.Global Incidence and Mortality for Prostate Cancer：Analysis of Temporal Patterns and Trends in 36 Countries[J].Eur Urol，2016，70（5）：862-874.
[11]	McNeal J.Pathology of benign prostatic hyperplasia insight into etiology[J].Urol Clin North Am，1990，17（3）：477-491.
[12]	Silsirivanit A.Glycosylation markers in cancer[J].Adv Clin Chem，2019，89：189-213.
[13]	李朝明，周鹏，徐啊白，等.经尿道前列腺解剖性剜除术治疗良性前列腺增生前后前列腺特异性抗原的变化[J].广东医学，2015，36（21）：3348-3350.
[14]	Park SC，Shin YS，Zhang LT，et al.Prospective investigation of change in the prostate-specific antigens after various urologic procedures[J].Clin Inter Aging，2015，10：1213-1218.
[15]	Acquaye J，Borofsky MS.Investigational procedures in benign prostatic hypertrophy[J].Curr Opin Urol，2018，28（3）：315-321.
[16]	Chung ASJ，Woo HH2.Update on minimally invasive surgery and benign prostatic hyperplasia[J].Asian J Urol，2018，5（1）：22-27.